230 related articles for article (PubMed ID: 30606948)
1. Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation.
Mendes TC; Simon A; Menezes JCV; Pinto EC; Cabral LM; de Sousa VP
Chem Pharm Bull (Tokyo); 2019; 67(1):23-31. PubMed ID: 30606948
[TBL] [Abstract][Full Text] [Related]
2. Development of a Dissolution Method for Gliclazide Modified-Release Tablets Using USP Apparatus 3 with in Vitro-in Vivo Correlation.
Bezerra KC; Pinto EC; Cabral LM; de Sousa VP
Chem Pharm Bull (Tokyo); 2018; 66(7):701-707. PubMed ID: 29962453
[TBL] [Abstract][Full Text] [Related]
3. Influence of dissolution media pH and USP1 basket speed on erosion and disintegration characteristics of immediate release metformin hydrochloride tablets.
Desai D; Wong B; Huang Y; Tang D; Hemenway J; Paruchuri S; Guo H; Hsieh D; Timmins P
Pharm Dev Technol; 2015; 20(5):540-5. PubMed ID: 24621340
[TBL] [Abstract][Full Text] [Related]
4. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
[TBL] [Abstract][Full Text] [Related]
5. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
6. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III.
Li J; Yang L; Ferguson SM; Hudson TJ; Watanabe S; Katsuma M; Fix JA
AAPS PharmSciTech; 2002; 3(4):E33. PubMed ID: 12916927
[TBL] [Abstract][Full Text] [Related]
8. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
[TBL] [Abstract][Full Text] [Related]
9. Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
Mohamed MF; Trueman S; Othman AA; Han JH; Ju TR; Marroum P
AAPS J; 2019 Oct; 21(6):108. PubMed ID: 31654328
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.
Takka S; Sakr A; Goldberg A
J Control Release; 2003 Feb; 88(1):147-57. PubMed ID: 12586512
[TBL] [Abstract][Full Text] [Related]
11. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations.
Rohrs BR; Burch-Clark DL; Witt MJ; Stelzer DJ
J Pharm Sci; 1995 Aug; 84(8):922-6. PubMed ID: 7500274
[TBL] [Abstract][Full Text] [Related]
12. In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
da Silva JD; de Sousa VP; Cabral LM; Davanço MG; Meulman J; de Oliveira Carvalho P; Campos DR
AAPS PharmSciTech; 2020 Jul; 21(5):195. PubMed ID: 32666354
[TBL] [Abstract][Full Text] [Related]
13. In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration.
Li ZQ; Tian S; Gu H; Wu ZG; Nyagblordzro M; Feng G; He X
AAPS PharmSciTech; 2018 May; 19(4):1882-1893. PubMed ID: 29663288
[TBL] [Abstract][Full Text] [Related]
14. Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
Lim JY; Kim TH; Song CH; Kim DH; Shin BS; Shin S
J Control Release; 2022 Mar; 343():443-456. PubMed ID: 35124130
[TBL] [Abstract][Full Text] [Related]
15. Gamma scintigraphic study of the hydrodynamically balanced matrix tablets of Metformin HCl in rabbits.
Razavi M; Karimian H; Yeong CH; Sarji SA; Chung LY; Nyamathulla S; Noordin MI
Drug Des Devel Ther; 2015; 9():3125-39. PubMed ID: 26124637
[TBL] [Abstract][Full Text] [Related]
16. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.
Balan G; Timmins P; Greene DS; Marathe PH
J Pharm Sci; 2001 Aug; 90(8):1176-85. PubMed ID: 11536222
[TBL] [Abstract][Full Text] [Related]
17. Development of an In Vitro Drug Release Method to Enable In Vitro-In Vivo Correlation of Potassium Chloride Extended-Release Tablets.
Qiu Y; Zhu DA; Apfelbaum K; Zu H; Xiong H
Mol Pharm; 2022 Nov; 19(11):4191-4198. PubMed ID: 36049021
[TBL] [Abstract][Full Text] [Related]
18. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product.
Qureshi SA; McGilveray IJ
Eur J Pharm Sci; 1999 Feb; 7(3):249-58. PubMed ID: 9845813
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
Lu Z; Fassihi R
AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
[TBL] [Abstract][Full Text] [Related]
20. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB
Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
